Journal ArticleDOI
Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.
TLDR
Increased serum creatinine and urea values indicated long-term renal toxicity and selective morphological changes in kidney cortex of nude mice were quantified and appeared in a dose dependent manner after injection of high amounts of [(177)Lu]-DOTATATE.About:
This article is published in Nuclear Medicine and Biology.The article was published on 2012-08-01. It has received 39 citations till now. The article focuses on the topics: Renal cortex & Kidney.read more
Citations
More filters
Journal ArticleDOI
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Kristell L.S. Chatalic,Sandra Heskamp,Mark Konijnenberg,Janneke D.M. Molkenboer-Kuenen,Gerben M. Franssen,Marian C. Clahsen-van Groningen,Margret Schottelius,Hans-Jürgen Wester,Wytske M. van Weerden,Otto C. Boerman,Marion de Jong +10 more
TL;DR: The preclinical application of PSMA I&T, a DOTAGA-chelated urea-based PSMA inhibitor, for SPECT/CT imaging and radionuclide therapy of prostate cancer is presented and indicates that PSMA-specific uptake in kidneys can be successfully tackled using blocking agents such as 2-PMPA.
Journal ArticleDOI
Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of Non-Hodgkin Lymphoma
Ahmet Krasniqi,Matthias D'Huyvetter,Catarina Xavier,Kevin Van der Jeught,Serge Muyldermans,José Van der Heyden,Tony Lahoutte,Tony Lahoutte,Jan Tavernier,Nick Devoogdt +9 more
TL;DR: Treatment of mice with 177Lu-DTPA-sdAb 9079 significantly prolonged median survival compared with control groups and was as effective as treatment with rituximab or its 177 Lu-labeled variant.
Journal ArticleDOI
Cadmium Nephrotoxicity Is Associated with Altered MicroRNA Expression in the Rat Renal Cortex
Michael J. Fay,Lauren A.C. Alt,Dominika Ryba,Ribhi Salamah,Ryan Peach,Alexander Papaeliou,Sabina Zawadzka,Andrew Weiss,Nil Patel,Asad Rahman,Zyaria Stubbs-Russell,Peter C. Lamar,Joshua R. Edwards,Walter C. Prozialeck +13 more
TL;DR: It is demonstrated that Cd significantly alters the miRNA expression profile in the renal cortex and raises the possibility that dysregulated miRNAs may play a role in the pathophysiology of Cd-induced kidney injury.
Journal ArticleDOI
Feasibility of simplifying renal dosimetry in 177 Lu peptide receptor radionuclide therapy
Anna Sundlöv,Johan Gustafsson,Gustav Brolin,Nadja Mortensen,Rebecca Hermann,Peter Bernhardt,Peter Bernhardt,Johanna Svensson,Michael Ljungberg,Jan Tennvall,Katarina Sjögreen Gleisner +10 more
TL;DR: Performing one SPECT/CT at 96 h in every treatment cycle gives sufficiently reliable dosimetric results to base individualized treatment planning on, with a reasonable demand on resources.
Journal ArticleDOI
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy
TL;DR: Recent advances in synthetic nanoparticles for radiotherapy and radiosensitization are reviewed, with a focus on the enhancement of in vivo anti-tumor activities.
References
More filters
Journal ArticleDOI
Tolerance of normal tissue to therapeutic irradiation.
B. Emami,John Lyman,A.P. Brown,Lawrence R. Coia,Michael Goitein,John E. Munzenrider,Brenda Shank,Lawrence J. Solin,Michael F. Wesson +8 more
TL;DR: The updated information on tolerance of normal tissues of concern in the protocols of this contract, based on available data, is presented, with a special emphasis on partial volume effects.
Journal ArticleDOI
Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom,Wouter W. de Herder,Boen L. Kam,Casper H.J. van Eijck,Martijn van Essen,P. P. M. Kooij,Richard A Feelders,Maarten O. van Aken,Eric P. Krenning +8 more
TL;DR: Treatment with peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate has few adverse effects and compares favorably to the limited number of alternative treatment modalities.
Journal ArticleDOI
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Maria A. Kouvaraki,Jaffer A. Ajani,Paulo M. Hoff,Robert A. Wolff,Douglas B. Evans,Richard D. Lozano,James C. Yao +6 more
TL;DR: Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS, and the volume of metastases in the liver is the most important predictor of outcome.
Journal ArticleDOI
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
Lisa Bodei,Marta Cremonesi,Mahila Ferrari,Monica Pacifici,Chiara Maria Grana,Mirco Bartolomei,Silvia M. Baio,Maddalena Sansovini,Maddalena Sansovini,Giovanni Paganelli +9 more
TL;DR: The results indicate the importance of clinical screening for risk factors and Fractionation of therapy is important in order to decrease toxicity, and further studies are needed to evaluate its clinical impact.
Journal ArticleDOI
Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281
TL;DR: FU/STZ improved survival compared with the doxorubicin-based regimen, suggesting that the combination should be considered to be an active regimen of therapy when chemotherapy is judged to be a option for selected patients with carcinoid tumors.